Frequencies of an Immunogenic HER-2/neu Epitope of CD8+T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer

HER-2/neu is the human epidermal growth factor receptor 2, which is associated with the progression of prostate cancer (PCa). HER-2/neu-specific T cell immunity has been shown to predict immunologic and clinical responses in PCa patients treated with HER-2/neu peptide vaccines. However, its prognostic role in PCa patients receiving conventional treatment is unknown, and this was addressed in this study. The densities of CD8+ T cells specific for the HER-2/neu((780-788)) peptide in the peripheral blood of PCa patients under standard treatments were correlated with TGF-beta/IL-8 levels and clinical outcomes. We demonstrated that PCa patients with high frequencies of HER-2/neu((780-788))-specific CD8+ T lymphocytes had better progression-free survival (PFS) as compared with PCa patients with low frequencies. Increased frequencies of HER-2/neu((780-788))-specific CD8+ T lymphocytes were also associated with lower levels of TGF-beta and IL-8. Our data provide the first evidence of the predictive role of HER-2/neu-specific T cell immunity in PCa.

Automated summary

This study investigated the prognostic role of HER-2/neu-specific T cell immunity in prostate cancer patients. The results showed that high frequencies of HER-2/neu-specific CD8+ T lymphocytes were associated with better progression-free survival and lower levels of TGF-beta and IL-8 in patients receiving standard treatment.